Hepatitis E Diagnostic Tests Market to Surge USD 78.62 Million by 2032, Driven by 4.6% CAGR | Polaris Market Research
August 14, 2024 08:40 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Market Overview: The Hepatitis E diagnostic tests market was estimated at USD 53.05 million in 2023. The market valuation is expected to be USD...
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Hepatitis: The silent killer
May 17, 2024 12:37 ET
|
Missouri Department of Health and Senior Services
May is Hepatitis Awareness Month, the perfect time for individuals to talk to their health care providers about hepatitis vaccinations.
Infectious Disease Diagnostics Market to Hit $37.94 Billion, Globally, by 2028 – Exclusive Report by The Insight Partners
September 20, 2023 10:22 ET
|
The Insight Partners
Pune, India., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tuberculosis (TB) is the 13th most significant cause of mortality globally and the second leading infectious disease after COVID-19, according to the...
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
July 11, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Anti-Viral Therapies Market Growth ($82.92 Billion by 2028) Driven by Branded Drugs Segment during (2022-2028) – Global Report by The Insight Partners
March 09, 2023 08:46 ET
|
The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
September 22, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed toreduce HDV viremia and block viral entry – SAN...